Market News & Trends
Gerresheimer to Sell Life Science Research Business
In line with its strategy of focusing on packaging and device solutions for pharmaceutical customers, Gerresheimer recently announced that it is to sell its Life…
Bayer Clinches Monsanto With Improved $66-Billion Bid
German drugs and crop chemicals company Bayer has won over US seeds firm Monsanto with an improved takeover offer of around $66 billion, ending months…
Dipexium Pharmaceuticals Announces Issuance of Patent
Dipexium Pharmaceuticals, Inc. recently announced that the European Patent Office has issued a new Locilex patent in the European Union (EU). The patent claims are…
Crown Bioscience Launches New Translational Platforms
Crown Bioscience, a global drug discovery and development services company providing translational platforms to advance metabolic disease and oncology research, will be announcing the release…
Capsugel Investing in Enhanced Micronization Capacity & Capabilities
Capsugel, a global leader in delivering high-quality, innovative dosage forms and solutions, recently announced an expansion of its facility in Quakertown, PA, to meet increasing…
Boost Vaccination Data Encourage Continued Development of Parkinson's Vaccine
AFFiRiS AG recently announced results of AFF008A, a Phase I clinical trial to assess boost immunizations with AFFITOPE PD01A, an active vaccine against Parkinson's disease…
Fuji Health Science Announces Name Change
Fuji Health Science, Inc. recently announced that as of September 1, 2016, the name of the entity has become Fuji Chemical Industries USA, Inc. to…
Allergan Acquires Gene Therapy Company
Allergan plc recently announced it has acquired substantially all of the assets of RetroSense in an all-cash transaction. Under the terms of the transaction, Allergan…
Niagara University Faculty Present Groundbreaking Research, New Insulin Pill For Diabetes Patients
NIAGARA UNIVERSITY, N.Y. - The need for painful insulin injections by certain diabetes patients may be eliminated with the introduction of a new technique…
Aptar Pharma Announces Development & License Agreement With BD
Aptar Pharma Announces Development & License Agreement With BD Aptar Pharma, a leading drug delivery solutions provider and segment of AptarGroup, Inc.…
Results From Preclinical Research & Phase Ib Study of Biogen’s Investigational Alzheimer’s Disease Treatment Published
Results from preclinical research and PRIME, the Phase Ib study of Biogen’s investigational treatment for early Alzheimer’s disease (AD), aducanumab, were published in a recent…
SteadyMed Announces Completion of Pre-NDA Submission Manufacturing Activities
SteadyMed Ltd. (Nasdaq:STDY), a specialty pharmaceutical company focused on the development of drug product candidates to treat orphan and high-value diseases with unmet parenteral delivery…
SGS Opens New Dedicated Facility for Extractables & Leachables Testing
SGS, a leading bio/pharmaceutical analytical and bioanalytical contract solutions provider, recently announced it has opened a new facility in Wiesbaden, Germany, exclusively to offer extractables…
Dalton Announces Completion of a Major Expansion in Sterile Filling & API Manufacturing
Dalton Pharma Services, a privately owned Canadian pharmaceutical services provider to leading pharmaceutical and biotechnology companies, recently announced the completion of a $5-million expansion in…
Cytokinetics & Amgen to Advance Drug to Phase III Clinical Development
Cytokinetics, Inc. recently announced the advancement of omecamtiv mecarbil to Phase III clinical development with a cardiovascular outcomes clinical trial expected to initiate in the…
Avantor Performance Materials & NuSil Technology to Merge
Avantor Performance Materials and NuSil Technology LLC, both portfolio companies of New Mountain Capital LLC, have signed a definitive agreement to merge. This merger will…
CordenPharma Chenôve Receives Successful FDA Inspection
CordenPharma is pleased to announce that their CordenPharma Chenôve (France) manufacturing facility recently completed an FDA Inspection and received a successful response with no…
BioTelemetry Agrees to License Proprietary Technology to Bloom Technologies
BioTelemetry, Inc. recently announced it has entered into a strategic partnership with Bloom Technologies, Inc. Under the terms of the agreement, Bloomlife will pay BioTelemetry…
BioPharmX Enrolls First Subject in OPAL Phase IIb Clinical Trial
BioPharmX Corporation recently announced that the first subject has been enrolled in its Phase IIb clinical trial assessing the efficacy and safety of BPX-01 for…
Novel Gene Therapy Drug for Huntington's Disease Reported
Data from Vybion on a novel treatment for Huntington's disease has been published in the Journal of Neurodegenerative diseases. The published study (http://www.hindawi.com/journals/jnd/2016/7120753/) links the…
